Bd, labcorp collaborate to develop flow cytometry-based companion diagnostics for matching patients with treatments

Companies combine key capabilities to advance flow cytometry as an essential companion diagnostic modality for cancer and other diseases franklin lakes, n.j. , aug. 9, 2022 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced a collaboration agreement with labcorp (nyse: lh), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (cdx) intended to match patients with life-changing treatments for cancer and other diseases.
BDX Ratings Summary
BDX Quant Ranking